By Fineline Cube Harbour BioMed (HKG: 2142) announced that China’s National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for HBM7004, a novel bispecific antibody (BsAb) targeting B7H4 and CD3, for the treatment of advanced solid tumors, following recent U.S. regulatory clearance in May 2026.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Harbour BioMed (HKG: 2142) |
| Drug Candidate | HBM7004 |
| Drug Class | Bispecific antibody (B7H4 x CD3) |
| Development Platform | Harbour Bispecific Immunocyte Engager (HBICE) |
| Regulatory Authorities | NMPA (China) – IND accepted; FDA (U.S.) – cleared May 2026 |
| Target Indication | Advanced solid tumors |
| Status | IND accepted for clinical trial review |
| Announcement Date | 11 Jun 2026 |
Drug Profile & Mechanism of Action
- Molecule: HBM7004 – bispecific antibody engaging B7H4 (tumor antigen) and CD3 (T-cell receptor)
- Platform: Harbour Bispecific Immunocyte Engager (HBICE) technology
- Mechanism: Intratumoral B7H4-dependent T-cell activation, redirecting cytotoxic T-cells specifically to B7H4-expressing tumor cells
- Preclinical Efficacy: Demonstrated potent anti-tumor activity across multiple animal models
- Safety Profile: Excellent in vivo stability with low systemic toxicity
- Combination Potential: Strong synergistic effects observed when combined with B7H4x4-1BB bispecific antibody, particularly under low effector-to-target cell ratios
B7H4 represents an emerging tumor-associated antigen overexpressed in multiple solid tumor types including ovarian, breast, lung, and endometrial cancers, while showing limited expression in normal tissues. HBM7004’s dual-targeting approach leverages this differential expression to achieve tumor-selective T-cell activation, potentially minimizing off-tumor toxicities commonly associated with conventional T-cell engagers.
Market Impact & Development Strategy
- Solid Tumor Market: Addresses significant unmet need in advanced solid tumors where current immunotherapies show limited efficacy
- Competitive Differentiation: One of few B7H4-targeting bispecific antibodies in clinical development globally
- Dual Jurisdiction Strategy: Simultaneous U.S. and China development accelerates global clinical timelines and de-risks regulatory pathways
- Platform Validation: Success of HBM7004 validates Harbour’s HBICE platform for future bispecific antibody candidates
- Combination Therapy Potential: Preclinical synergy data supports rapid advancement into combination regimens, potentially expanding therapeutic window and efficacy
- Commercial Outlook: Peak annual sales potential estimated at USD 300-500 million if approved, targeting B7H4-positive tumor populations representing approximately 15-20% of all solid tumors
The IND acceptance positions Harbour BioMed as a leader in next-generation bispecific antibody development and demonstrates the company’s capability to advance innovative immuno-oncology assets through parallel regulatory pathways in major global markets.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and market opportunities. Actual outcomes may differ due to clinical trial results, regulatory decisions, and competitive developments inherent in oncology drug development.-Fineline Info & Tech